| Literature DB >> 33841626 |
Yu-Shui Ma1,2,3, Rui Xin3, Xiao-Li Yang3, Yi Shi2, Dan-Dan Zhang3, Hui-Min Wang2, Pei-Yao Wang3, Ji-Bin Liu2, Kai-Jian Chu4, Da Fu3.
Abstract
Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins, which have a low molecular weight, making them penetrate cells easily. Small-molecule drugs can be developed from leads derived from rational drug design or isolated from natural resources. As commonly used medications, small-molecule drugs can be taken orally, which enter cells to act on intracellular targets. These characteristics make small-molecule drugs promising candidates for drug development, and they are increasingly favored in the pharmaceutical market. Despite the advancements in molecular genetics and effective new processes in drug development, the drugs currently used in clinical practice are inadequate due to their poor efficacy or severe side effects. Therefore, developing new safe and efficient drugs is a top priority for disease control and curing. AJTRKeywords: Small-molecule drugs; cancer; compound; molecular genetics; natural resource
Year: 2021 PMID: 33841626 PMCID: PMC8014367
Source DB: PubMed Journal: Am J Transl Res ISSN: 1943-8141 Impact factor: 4.060